Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Jan Stefan Scheld to Helm Nippon Boehringer Ingelheim
July 5, 2023
- Eisai CEO Confident on US Full Approval for Leqembi
July 5, 2023
- Teijin, Axcelead Seal Definitive Accord to Form Drug Discovery JV
July 4, 2023
- Chugai Is Best-Paying Japan Pharma Again in FY2022, 5 Drug Makers Top 10 Million Yen
July 4, 2023
- AstraZeneca Seeks Label Expansion for Synagis in Japan
July 4, 2023
- Kissei Adopts Iktos’ AI-Powered Drug Discovery System
July 4, 2023
- Maruho, Tsukuba Startup Ink ALDH2 Activator Deal
July 4, 2023
- 32 Pharma Execs Take Home Over 100 Million Yen in FY2022, Top 3 from Takeda: Securities Reports
July 3, 2023
- Meiji Seeks Booster Nod for COVID-19 mRNA Vaccine in Japan
July 3, 2023
- AstraZeneca Exits PhRMA in Japan after Global Decision
July 3, 2023
- Eisai Transfers Economic Rights for Breast Cancer Med to DRI
July 3, 2023
- Takeda Files Acquired Hemophilia A Therapy in Japan
July 3, 2023
- Shionogi’s Mulpleta Approved in China
July 3, 2023
- Taisho Launches 2nd Voluntary Redundancy Program
June 30, 2023
- Pfizer Japan Files BCMA Bispecific Elranatamab for MM
June 30, 2023
- CAR-T Player Noile-Immune Goes Public on TSE
June 30, 2023
- Shionogi Launches PIII Pediatric Study for Xocova in Japan
June 30, 2023
- Takeda CEO Touts Aggressive Dividend Policy as Deleveraging Drive Hits Goal
June 29, 2023
- Chugai Trims 150 Reps via Voluntary Buyout, Sales Force Down to 1,050 from July
June 29, 2023
- Astellas’ Hot Flash Med Nets Positive PIIIb Results in Europe
June 29, 2023
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…